
    
      The primary objective of the study is to determine whether modafinil at 255, 340, 425, or 510
      mg'day is more effective than a placebo in alleviating the symptoms of
      Attention-Deficit/Hyperactivity Disorder (ADHD) in adults as determined by the change from
      baseline in the total score from the investigator-completed Adult ADHD Investigator Symptoms
      Rating Scale (AISRS) the at endpoint (last post-baseline observation [week 9 or early
      termination]).
    
  